focus -WSS

focus

author：leisure time 2025-09-30 05:33:40 Page View：8

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Quicker fix for pulse oximeters urged during FDA public meeting
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

comprehensive

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

InsitroCEOandfounderDaphneKollerNeilsonBarnard/GettyImagesforTheNewYorkTimesSANFRANCISCO—Ittookonlya

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Photoillustration:STAT;Photo:AdobeThreeyearsago,JamieLin,anearly-careernephrologistatMDAndersonCance